Ann: PTX-100 clinical data presented at leading TCL meeting, page-9

Hi Shellbell, l believe you are correct in regard to PTCL. Also if the early patient reports from Ph 2 CTCL are favorable and do meet the safety requirements l am sure James Mc Donnell would have some interested companies in the background more than willing to be financially involved. Now we have been officially notified that in April the Ph2 PTX100 patients will be established and treated soon after l look forward to the results, my information reads that because our next cohort of patients are starting off with only having 1 or 2 prior treatments the results should be very good. All in all we are in a good place at the moment in regard to our trajectory. Logan